Popular terms

Rheumatoid Arthritis topics
Rheumatoid Arthritis
Osteoarthritis
Autoimmune
Multiple Sclerosis
Immune Disease
Autoimmune Disease
Antibodies
Astaxanthin
Hyaluronate
Hyaluronic Acid
Joint Pain
Hyaluronan
Immune Diseases
Autoimmune Diseases
Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Rheumatoid Arthritis patents



      

This page is updated frequently with new Rheumatoid Arthritis-related patent applications.




Date/App# patent app List of recent Rheumatoid Arthritis-related patents
04/28/16
20160114062 
 Treatment of immune, inflammatory and degenerative arthritides with tin-117m patent thumbnailnew patent Treatment of immune, inflammatory and degenerative arthritides with tin-117m
Immune, inflammatory and degenerative arthritides, including rheumatoid arthritis, hemophiliac arthropathy and osteoarthritis, can be treated using a systemic or intra-articular radiosynovectomy technique in which the radionuclide is high specific activity tin-117m. Tin-117m can either be bound to a colloid typically used in an intra-articular radiosynovectomy (rsv), or can be tin-117m annexin for rsv and systemic administration..
Rheumco Llc


04/21/16
20160109442 
 Novel test  rheumatoid arthritis and kit for rheumatoid arthritis test patent thumbnailNovel test rheumatoid arthritis and kit for rheumatoid arthritis test
Provided are: a novel test method for rheumatoid arthritis; and a kit for rheumatoid arthritis test, which is used in the novel test method for rheumatoid arthritis. A test method for rheumatoid arthritis according to the present invention is characterized by comprising a step for measuring the amount of talin in the plasma or serum of an animal subject.

04/21/16
20160106905 
 Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders patent thumbnailTargeted apheresis for the treatment of rheumatoid arthritis and immune disorders
This invention uses “targeted apheresis” to treat patients with rheumatoid arthritis and other autoimmune and inflammatory disorders. “targeted apheresis” is a process whereby only the pathogenic and pro-inflammatory elements associated with the disease symptoms are simultaneously and selectively removed from the blood by passing the blood through an extracorporeal affinity device containing selective binding agents.

04/14/16
20160102098 
 Bisulfate of janus kinase (jak) inhibitor and preparation method therefor patent thumbnailBisulfate of janus kinase (jak) inhibitor and preparation method therefor
The present invention relates to a bisulfate of a janus kinase (jak) inhibitor and a preparation method therefor. More specifically, the present invention relates to a (3ar,5s,6as)-n-(3-methoxyl-1,2,4-thiadiazole-5-group)-5-(methyl(7h-pyrrolo[2,3-d]pyrimidine-4-group)amino)hexahydrocyclopenta[c]pyrrole-2(1h)-formamide bisulfate shown in the formula (i), a preparation method therefor, and an application thereof.

04/07/16
20160096899 
 Methods for treating juvenile arthritis with anti-bile salt-stimulated lipase (bssl) antibodies patent thumbnailMethods for treating juvenile arthritis with anti-bile salt-stimulated lipase (bssl) antibodies
It provides methods and pharmaceutical compositions comprising antagonists to the protein bile salt-stimulated lipase (bssl) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising bssl antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis.
Lipum Ab


04/07/16
20160096895 
 Binding members-513 patent thumbnailBinding members-513
This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (il-1r1). For example, isolated binding members specific for il-1r1 which competes with il-1 and il-1ra for binding to il-1r1 and binds il-1r1 with a kd of 10 pm or less when measured by kinexa™.
Medimmune Limited


03/31/16
20160091490 
 Compositions and methods for the diagnosis of rheumatoid arthritis patent thumbnailCompositions and methods for the diagnosis of rheumatoid arthritis
The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-carp) antibodies in the serum of rheumatoid arthritis (ra) patients.. .
Leiden University Medical Center


03/24/16
20160083415 
 Crystalline anhydrate forms of a pharmaceutical patent thumbnailCrystalline anhydrate forms of a pharmaceutical
The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates.
Harbor Therapeutics, Inc.


03/24/16
20160083354 
 Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same patent thumbnailNovel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (hdac) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (hdac) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc..
Chong Kun Dang Pharmaceutical Corp.


03/24/16
20160082017 
 Estriol therapy for multiple sclerosis and other autoimmune diseases patent thumbnailEstriol therapy for multiple sclerosis and other autoimmune diseases
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (ms), rheumatoid arthritis (ra), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis..

03/24/16
20160081578 

Biomarkers for the diagnosis and prognosis of back pain and related conditions


The present invention teaches novel methods of diagnosing and prognosing conditions associated with tissue degeneration and/or pain, including intervertebral disc degeneration, discogenic pain, osteoarthritis, rheumatoid arthritis, and articular cartilage injury. Using the inventive noninvasive imaging methods, the diagnosis and prognosis of back pain and related conditions can be quickly and accurately determined by detecting one or more biomarkers disclosed herein..
Cedars-sinai Medical Center


03/10/16
20160068552 

Vinblastine derivatives, preparation method therefor and application thereof


The present invention provides a new kind of vinca alkaloid derivatives, new applications thereof and preparation methods therefor. The vinca alkaloid derivatives comprise hydrazinolyzed vinca alkaloids and vinca alkaloid dipeptide derivative.
Jinan University


03/10/16
20160068539 

Protease inhibitors


Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.. .

03/03/16
20160058892 

Preparation of bone-seeking superparamagnetic iron nanoparticles as contrast agents and methods for using the same


Described herein are compositions having a nanoparticle that is conjugated to at least one bone targeting moiety, wherein the bone targeting moiety is bonded to the nanoparticle by a linker, wherein the nanoparticle contains iron, and wherein the compositions are neutral or pharmaceutically acceptable salts or esters. Also described herein are methods of making these compositions.
The Governors Of The University Of Alberta


02/25/16
20160053007 

Antibodies that bind to tl1a and methods of treating inflammatory or autoimmune disease comprising administering such antibodies


Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between dr3 and tl1a. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a t cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services


02/25/16
20160053004 

Nucleic acides encoding anti-c5a antibodies


The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. .
Alexion Pharmaceuticals, Inc.


02/25/16
20160051570 

Treatment of rheumatoid arthritis


A composition for treating chronic inflammation, including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and vitamin d in synergistically effective amounts. A method of treating chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and vitamin d to an individual suffering from chronic inflammation, and treating chronic inflammation.
Ganderland And Associates, Inc.


02/18/16
20160046719 

Antibodies that bind colony stimulating factor 1 receptor (csf1r)


Antibodies that bind csf1r are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind csf1r are also provided.
Five Prime Therapeutics, Inc.


02/18/16
20160046627 

Itk and jak kinase inhibitors


Salts thereof, their synthesis, and their use as itk and jak3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention..

02/18/16
20160046612 

Heterocyclic derivative and pharmaceutical drug


Wherein r1 and r2 are the same or different aromatic rings, etc., and ring a is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mpges-1 inhibiting activity and is useful as an agent for the treatment or prevention of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease..

02/18/16
20160045520 

Use in one pill tablet capsule minocycline acycloguanosine atorvastatin and vitamin d3 in the treatment of rheumatoid arthritis


The present invention has for object the use of minocycline or its equivalent forms, or any form of tetracycline in combination with acycloguanosine or any equivalent form (antiviral), atorvastatin or any equivalent form (lipophilic statins) and vitamin d3 (pro hormone) for the preparation of a single compound addressed to treatment of autoimmune type of rheumatoid arthritis in the three stages of development, whether it is active or quiescent phase or forms of diseases eziopatologicamente equivalent, but some degenerative. The efficacy of this combination has been proven by many studies on individual components.

02/18/16
20160045516 

Treatment methods using pharmaceutical solid state forms


The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates.
Harbor Therapeutics, Inc.


02/18/16
20160045475 

Methods for the treatment of diseases ameliorated by pde4 inhibition using dosage titration of apremilast


Methods of treating, managing or preventing diseases ameliorated by inhibiting pde4 such as psoriasis, ankylosing spondylitis, behcet's disease, rheumatoid arthritis, atopic dermatitis, crohn's disease, and ulcerative colitis are disclosed. Specific methods encompass the administration of apremilast in specific dosage titration schedule, alone or in combination with a second active agent..
Celgene Corporation


02/11/16
20160039928 

Anti-il-17a antibodies and their use in treating autoimmune and inflammatory


The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17 a. The disclosure more specifically relates to specific antibodies and proteins that are il-17 a antagonists (inhibit the activities of il-17 a and il-17 af) and are capable of inhibiting il-17 a induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo.
Novartis Ag


02/11/16
20160039807 

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)


Wherein cy, l1, g, and r1 are as described herein. The present invention relates to novel compounds according to formula (i) that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g.

02/04/16
20160032001 

Anti-rankl antibodies and methods of use


The present invention provides anti-rankl monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.. .
Apexigen, Inc.


01/28/16
20160024580 

Polymorphism of thrombospondin-1 as a biomarker for susceptabiltiy to dry eye


Embodiments of the invention relate to single nucleotide polymorphisms (snps) in thrombospondin 1 gene (thb-s1) that are herein linked to an increased risk for dry eye (also known as keratoconjunctivitis). The polymorphisms disclosed herein are directly useful for the diagnosis of an increased risk for dry eye, as well as for the determination of patient treatment pre- and post-surgery (e.g.
Trustees Of Boston University


01/28/16
20160024220 

Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis


The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-cd6 monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


01/28/16
20160024082 

P2x7 modulators


The present invention is directed to a compound of formula (i) or (ia) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) or (ia) and methods comprising administering of compounds of formula (i) or (ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv


01/28/16
20160024074 

Process for extracting the alkaloid fraction of rhodophiala bifida (herb.) traub and uses thereof


The present invention describes a method for completely extracting the alkaloid fraction (montanine) of rhodophiala bifida (herb.) traub from bulbs of rhodophiala bifida. The present invention further describes a method for treating inflammation using pharmaceutical compositions containing the alkaloid fraction of rhodophiala bifida as the active ingredient.
Hospital De ClÍnicas De Porto Alegre (hcpa)


01/28/16
20160022692 

Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors


Provided herein are methods, kits, and pharmaceutical compositions that include a pi3 kinase inhibitor for treating rheumatoid arthritis or asthma.. .
Infinity Pharmaceuticals, Inc.


01/21/16
20160018407 

Metabolic profiles


The invention relates to the use of endogenous metabolites to produce a metabolic profile of a disorder or disease in a subject, e.g. An autoimmune disease, in particular rheumatoid arthritis, and the analysis of such metabolic profiles in order to find disturbances in such profiles in a subject which are caused by or correlated with the said diseases or disorders.
Anamar Ab


01/21/16
20160016962 

P2x7 modulators


The present invention is directed to a compound of formula (i) formula (i) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) and methods comprising administering to a subject at least one compound selected from compounds of formula (i) for treating diseases mediated by p2x7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv


01/21/16
20160015685 

Furo [3, 2-b] pyrr0l-3-0nes as cathespin s inhibitors


Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .

01/14/16
20160010089 

Organic compositions to treat epasi-related diseases


The present disclosure relates to methods of treating epas1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a rnai agent to epas1.. .
Arrowhead Research Corporation


01/14/16
20160009716 

2 - (azaindol-2-yl) benz imidazoles as pad4 inhibitors


Compounds of formula (i) wherein; r1 is hydrogen or c1-6alkyl; r2 is hydrogen, c1-6alkyl, perhalomethylc0-5alkyl-o—, or c1-6alkoxy; r3 is hydrogen, c1-6alkyl, or c1-6alkoxyc1-6alkyl; r4 is hydrogen, c1-6alkyl, perhalomethylc1-6alkyl; or unsubstituted c3-6cycloalkylc1-6alkyl; a is c—r5 or n; b is c—r6 or n; d is c—r7 or n; with the proviso that at least one of a, b, and d, is n; r5 is hydrogen or c1-6alkyl; r6 is hydrogen or c1-6alkyl; r7 is hydrogen, c1-6alkyl, c1-6alkoxy, or hydroxy; r8 is hydrogen or c1-6alkyl, with the proviso that one of r4 and r8 is hydrogen; r9 is hydrogen or hydroxy; rio is hydrogen or c1-6alkyl; and salts thereof are pad4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.. .
Glaxo Group Limited


01/07/16
20160002354 

Antibodies to bone marrow stromal antigen 1


The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd


01/07/16
20160002328 

Methods of treating kawasaki disease using il-1beta antibodies


This invention relates to a novel use of il-1β-ligand/il-1 receptor disrupting compounds (herein referred to as “il-1beta compounds”); such as small molecular compounds disrupting il-1b ligand-il-1 receptor interaction, il-1b antibodies or il-1 receptor antibodies, e.g. Il-1b binding molecules described herein, e.g.
Novartis Ag


01/07/16
20160002326 

Compositions and methods for treating rheumatoid arthritis


The treatment of rheumatoid arthritis using engineered multivalent and multispecific binding proteins that target tnf and il-17 is provided.. .
Abbvie Inc.


01/07/16
20160002295 

Methods and compositions for the treatment of bone remodeling disorders


The present invention relates to methods and compositions for treating disease related to disorders of bone remodeling. In particular, the present invention relates to compositions and methods for treating rheumatoid arthritis..
Yissun Research Development Company Of The Hebrew University Of Jerusalem, Ltd


01/07/16
20160002243 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula (i) wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


01/07/16
20160002206 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula i: (i) wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


01/07/16
20160000849 

Composition for remedying or treating rheumatoid arthritis and osteoarthritis


The present invention relates to the composition according to the present invention, which has not only the effect of suppressing inflammation and pain, which are the common symptoms of acute and chronic arthritis, but also the effect of alleviating movement disorders, which are the symptoms of chronic arthritis.. .
Hanpoong Pharm & Foods Co., Ltd.


01/07/16
20160000844 

A composition for improving joint health, or for preventing and treating rheumatoid arthritis and osteoarthritis


The present invention relates to a composition for helping with joint health or preventing, alleviating or treating rheumatoid arthritis and osteoarthritis, which is based on the results of tests conducted using an inflammatory cell model, an osteoarthritis animal model and an acute arthritis animal model.. .
Hanpoong Pharm & Foods Co., Ltd.


12/31/15
20150377907 

Diagnosis of rheumatoid arthritis


The present invention provides a method of diagnosing rheumatoid arthritis (ra), comprising: testing a sample from a subject for the presence or absence of antibodies against oxidised collagen ii; wherein the presence of antibodies against oxidised collagen ii in the sample is indicative of ra in the subject. The present invention also provides a method for identifying whether a subject responds to a disease modifying anti-rheumatic drug (dmard) and related methods of treating ra, a method for identifying whether a subject responds to an anti-tnf biologic and related methods of treating ra, and a method of diagnosing osteoarthritis (oa)..
King's Colege London


12/31/15
20150376701 

Biomarkers of autoimmune and/or chronic diseases associated with joint inflammation


The present invention relates to methods and uses of fcrl4 expression and optionally rankl expressing b cells as biomarkers and therapeutic target for treatment of an autoimmune and/or chronic diseases associated with joint inflammation, in particular rheumatoid arthritis (ra).. .
The University Of Birmingham


12/31/15
20150376294 

Anti-pad2 antibodies and treatment of autoimmune diseases


The present invention relates to anti-peptidylarginine deiminase 2 (pad2) antibodies and anti-pad2 antibodies for use in the treatment of autoimmune diseases characterized by extracellular citrullination, such as rheumatoid arthritis (ra). The invention further relates to a method for treatment of an autoimmune disease characterized by extracellular citrullination comprising the administration of a suitable amount of an anti-pad2 antibody to a subject..
Rigshospitalet


12/31/15
20150376285 

Antibody molecule for human gm-csf receptor alpha


Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (gm-csfrα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g.
Zenyth Operations Pty. Ltd.


12/31/15
20150376166 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula (i): wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


12/31/15
20150374700 

Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors


The present invention relates to chemical compounds of formula (i) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by tnf-α or by pde4, including but not limited to rheumatoid arthritis.. .
Vtv Therapeutics Llc


12/17/15
20150361176 

Ligands that bind tgf-beta receptor ii


The disclosure provides an anti-tgfbetarii immunoglobulin single variable domain. Suitably, an anti-tgfbetarii immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of seq id no:1-28 having up to 5 amino acid substitutions, deletions or additions.
Glaxo Group Limited


12/17/15
20150359814 

Pharmaceutical combinations of flurbiprofen, glucosamin and capsaicin


The present invention relates to a pharmaceutical combination of flurbiprofen or a pharmaceutically acceptable salt thereof, glucosamine or a pharmaceutically acceptable salt thereof and capsaicin or a pharmaceutically acceptable salt thereof. Particularly, the present invention relates to a pharmaceutical combination for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders, especially with osteoarthritis and rheumatoid arthritis..
Sanovel Ilac Sanayi Ve Ticaret A.s.


12/10/15
20150353538 

Compounds and therapeutic uses thereof


The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, t-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.. .
Alzheimer's Institute Of America, Inc.


12/10/15
20150353534 

Thiazole derivatives as inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula i: wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


12/10/15
20150352070 

Methods of treating diseases associated with high-fat diet and vitamin a deficiency using retinoic acid receptor agonists


This invention relates to pharmaceutical composition and methods of using vitamin a and/or rarb agonist for the treatment or prevention of diseases or conditions associated with high fat diet and/or vitamin deficiency. After smoking, high fat diet is said to be the second most lethal habit, causing 300,000 deaths each year in the u.s.
Cornell University


12/03/15
20150344934 

Novel high throughput assay for finding new jak3 interacting compounds, biomolecules, and inhibitors.


Janus kinase 3 is a non-receptor tyrosine kinase that mediates signals initiated by cytokines through interactions with the receptors of cytokines. Abnormal activation of jak3 was associated with human hematologic and epithelial malignancies.

12/03/15
20150344558 

Anti-il-6 antibodies for the treatment of arthritis


The present invention is directed to therapeutic methods using il-6 antagonists such as anti-il-6 antibodies and fragments thereof having binding specificity for il-6 to prevent or treat rheumatoid arthritis.. .
Alderbio Holdings Llc


12/03/15
20150344426 

Compounds and therapeutic uses thereof


The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, t-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.. .
Alzheimer's Institute Of America, Inc.


11/26/15
20150337041 

Methods and compositions for treating autoimmune diseases or conditions


The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to nkg2d receptors present on the surface of cells underlying the disorders..
Fred Hutchinson Cancer Research Center


11/26/15
20150336966 

Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders


The present invention relates to certain substituted tricyclic acid derivatives of formula (i) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the s1p1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer..
Arena Pharmaceuticals, Inc.


11/26/15
20150336964 

Fused heteroaromatic pyrrolidinones


And pharmaceutically acceptable salts thereof, wherein g, l1, l2, r1, r2, r3, and r4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of syk is indicated..

11/26/15
20150336884 

Novel synthetic antioxidants and their uses


The present invention relates to synthetic organic antioxidants of small molecules. The novel dithiol-containing compounds in this invention possess strongest possible capability as both scavenger for free radicals and antioxidant.

11/26/15
20150335739 

Methods for treating inflammation


The invention provides methods and compositions for inhibiting, reducing or slowing inflammation or inflammatory diseases, for reducing sequestration or collecting or localization of macrophages, for treating a disease caused all or in part by or characterized by inflammation such as, for instance, chronic inflammation, for inhibiting, slowing, reversing or preventing atherosclerosis, and for increasing insulin sensitivity, decreasing or inhibiting resistance to insulin, or treating diabetes by inhibiting, inhibiting the biological activity of or antagonizing an axonal guidance protein. The methods may feature administering to a subject a therapeutically effective amount of an agent effective to inhibit or reduce the biological activity of an axonal guidance protein or a receptor of the axonal guidance protein, or an analog, derivative or combination thereof.
New York University


11/26/15
20150335619 

Modulators of gtpases and their use


The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the ras-homologous (rho) family of small gtpases (e.g. Rac, cdc42 and rho gtpases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-b cell lymphoma, where these gtpases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of rho gtpases plays a pivotal role (menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type 1), huntington's disease and alzheimer's disease) which are mediated through these proteins.
Stc.unm


11/26/15
20150335618 

Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders


The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of formula (ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the s1p1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, microbial infections or diseases and viral infections or diseases..
Arena Pharmaceuticals, Inc.


11/19/15
20150330968 

Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions


The present invention relates to methods and assays for identifying agents capable of modulating gpr84 activity in cells, in particular agents that inhibit gpr84-agonist stimulated chemotaxis. Inhibition of gpr84-agonist stimulated chemotaxis is useful in the prevention and/or treatment of inflammatory conditions.
Galapagos Nv


11/19/15
20150329565 

Substituted triazole boronic acid compounds


The invention is concerned with the compounds of formula (i) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula i as well as pharmaceutical compositions containing such compounds.
Hoffmann-la Roche Inc.


11/12/15
20150322148 

Methods of using il-1beta compounds


This invention relates to methods employing il-1β-ligand/il-1 receptor disrupting compounds (herein referred to as “il-1beta compounds”); such as small molecular compounds disrupting il-1β ligand-il-1 receptor interaction, il-1β antibodies or il-1 receptor antibodies, e.g. Il-1β binding molecules as described herein, e.g.
Novartis Ag


11/05/15
20150317796 

Brain functional magnetic resonance activity is associated with response to tumor necrosis factor inhibition


The present invention relates to a non-invasive method for predicting the responsiveness of a human subject suffering from inflammatory disease to a treatment with a therapy against said inflammatory disease using brain imaging techniques. Furthermore, the present invention relates to a pharmaceutical composition comprising an active ingredient for the treatment of human subjects suffering from inflammatory disease and being identified as responders to therapy against the inflammatory disease according to the method of the invention.
Universitätsklinikum Erlangen


11/05/15
20150315280 

Preventive or remedy for inflammatory disease


The present inventors obtained, from a phage library of human antibodies, an anti-mouse nr 10 neutralizing antibody-expressing bm095 clone that shows a strong proliferation-suppressing activity in an il-31-dependent ba/f3 cell proliferation assay system. When this anti-mouse nr 10 neutralizing antibody was administered to nc/nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed.
Chugai Seiyaku Kabushiki Kaisha


10/29/15
20150306132 

Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha


Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.. .
U.s. Nutraceuticals, Llc D/b/a Valensa International


10/22/15
20150301041 

Assay method


A method of determining the likelihood of a patient developing rheumatoid arthritis (ra) is provided, which relies on the use of adipor1 and/or adipor2 in leukocytes as prognostic markers. The method may comprise determining the expression of a dipor1 and/or adipor2 in leukocytes in a sample from said patient.
The University Of Birmingham


10/22/15
20150299710 

Inhibitory oligonucleotide and use thereof


The inhibitory oligonucleotides (odns) which strongly block nf-κb activation induced by tlr9 agonists and tlr7 agonists are provided. The production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor alpha, is inhibited by the inhibitory-odns.
Sbi Biotech Co., Ltd.


10/22/15
20150299252 

Compositions and methods for modulating innate and adaptive immune systems


Compositions and methods useful in modulating the innate and adaptive immune systems in a subject, including activation of natural killer (nk) cells and/or cd8+ cytotoxic t lymphocytes. The method typically comprises: administering to the subject a composition comprising a therapeutic peptide or a multivalent structured polypeptide comprising multiple copies of the therapeutic peptide described herein in an amount sufficient to increase activity of nk cells and/or cd8+ cytotoxic t lymphocytes in the subject.
Susavion Biosciences, Inc.


10/22/15
20150299171 

Inhibitors of bruton's tyrosine kinase


The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by formula (iv), or a pharmaceutically acceptable salt, solvate, metabolites, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (btk) inhibitors and is further useful to treat inflammatory, auto immune diseases associated with aberrant b-cell proliferation such as ra (rheumatoid arthritis) and cancers.
Centaurus Biopharma Co., Ltd.


10/22/15
20150299143 

Substituted triazole and imidazole compounds


The invention is concerned with the compounds of formula (i): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (i) as well as pharmaceutical compositions containing such compounds.
F. Hoffmann-la Roche Ag


10/22/15
20150299125 

Prodrug bipyridylaminopyridines as syk inhibitors


The present invention provides compounds of formula (i), which are prodrugs of trans-4-[(1r)-(6-{[4-(difluoromethyl)pyridin-2-yl]amino}-4-methyl-2,3′-bipyridin-6′-yl)-1-hydroxyethyl]cyclohexanecarboxylic acid, a potent inhibitor of syk. The compounds are useful in the treatment and prevention of diseases mediated by the enzyme, such as asthma, copd, rheumatoid arthritis and cancer..
Merck Sharp & Dohme Corp.


10/15/15
20150293120 

Marker sequences for rheumatoid arthritis


The present invention relates to a novel method for identifying marker sequences for rheumatoid arthritis, the novel marker sequences discovered with the aid of the method, and the diagnostic use thereof. The invention also relates to diagnostic devices containing such marker sequences for rheumatoid arthritis, in particular a protein biochip or beads (pellets), and use thereof..

10/15/15
20150291689 

Compositions and methods for treating rheumatoid arthritis


Proteins that bind both il-17 and tnf are described along with their use in compositions and methods for treating, preventing, and ameliorating rheumatoid arthritis.. .

10/15/15
20150291525 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula (i): wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.

10/15/15
20150290270 

Synergistic anti-inflammatory compositions comprising boswellia serrata extract


The present invention discloses synergistic nutraceutical or pharmaceutical or dietary supplement anti-inflammatory compositions comprising therapeutically effective combination of an extract selectively enriched in 3-o-acetyl-1 1-keto-β-boswellic acid (akba) derived from boswellia serrata and boswellia serrata non-acidic resin extract (bnre). The composition(s) can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, osteoarthritis, rheumatoid arthritis, endothelial dysfunction and the like.

10/15/15
20150290231 

Composition for inhibiting cellular senescence comprising quercetin-3-o-beta-d-glucuronide


The present invention relates to a composition for inhibiting cellular senescence comprising quercetin-3-o-β-d-glucuronide (q3ga) as an active ingredient, and provides a composition for inhibiting cellular senescence of fibroblasts or umbilical vein endothelial cells induced by adriamycin or replicative senescence of fibroblasts or umbilical vein endothelial cells. Specifically, the quercetin-3-o-β-d-glucuronide (q3ga) is characterized by being isolated from polygoni avicularis herba extract.

10/08/15
20150284426 

Prodrug of an ice inhibitor


Compound i is useful for treating il-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, alzheimer's disease, myocardial infarction, congestive heart failure, huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.. .

10/08/15
20150284394 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula i wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.

10/08/15
20150283127 

Saquinavir-no for immunomodulation


The nitric ester of saquinavir, or its non-toxic salts, solvates or crystalline/polymorphic forms, i useful in the treatment of autoimmune diseases, particularly in disease mediated by pro-inflammatory cytokines. Examples of diseases which may be treated include idiopathic addison's disease, autoimmune hepatitis, biliary cirrhosis, primary sclerosing cholangitis, guillain barré syndrome, hashimoto's thyroiditis, psoriasis, rheumatoid arthritis, sjogren's syndrome, systemic lupus erythematous, type 1 diabetes mellitus and uveitis of ischemia-reperfusion, graft versus host diseases, graft rejection, endo and exo-toxemia and gouty arthritis..

10/08/15
20150283117 

Triazolone compounds as mpges-1 inhibitors


The present disclosure is directed to compounds of formula (i), and pharmaceutically acceptable salts thereof, as rapges-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin e synthase-1 (mpges-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases..

10/01/15
20150274825 

Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)


The invention relates to antibodies that are capable of specifically binding trem-1 and preventing the activation of trem-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease..
Novo Nordisk A/s


10/01/15
20150274777 

Ketoamide immunoproteasome inhibitors


The invention is concerned with the compounds of formula (i): and pharmaceutically acceptable salts thereof, wherein x, r1, r1′, r2, r2′, r3, r4, r4′ and r5 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (i) as well as pharmaceutical compositions containing such compounds.
Hoffmann-la Roche Inc.


10/01/15
20150274723 

Substituted 6-aza-isoindolin-1-one derivatives


And pharmaceutically acceptable salts thereof, wherein g, p, r1, r2, r3a, r4, and r5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of syk is indicated..

10/01/15
20150272936 

Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor


This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, copd). The method comprises administering a pi3k delta inhibitor or a dual pi3k delta-gamma inhibitor and a pde4 inhibitor.
Rhizen Pharmaceuticals Sa


09/24/15
20150266951 

Novel epitope of ip-10 and antibody to same


The present invention relates to a novel epitope of ip-10 (ifn-γ-inducible protein 10), to an antibody to the epitope or an antigen-binding fragment thereof, to a composition comprising the epitope as an active ingredient for inducing an antibody to ip-10, and to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof for preventing or treating diseases relating to ip-10. The anti-ip-10 antibody of the present invention can be effectively used in preventing or treating various diseases relating to ip-10 such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus..
Snu R&db Foundation


09/24/15
20150266920 

Macrocyclic ketoamide immunoproteasome inhibitors


And pharmaceutically acceptable salts thereof, wherein x, y, z, r1, r2, r3 and r3′ are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula i as well as pharmaceutical compositions containing such compounds.

09/24/15
20150266815 

Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use


The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “apsac compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (copd), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc..
Pimco 2664 Limited


09/24/15
20150265647 

Uridine diphosphate derivatives, prodrugs, compositions and uses thereof


This disclosure relates to the use of uridine diphosphate (udp) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of udp derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the udp derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., alzheimer's disease, parkinson's disease) and traumatic cns injury, pain, down syndrome (ds), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.. .
Tufts University


09/24/15
20150265460 

Installation for general air cryotherapy


The proposed invention relates to the field of physical therapy and can be used for the treatment and prophylaxis of a number of diseases, and also for health-improving purposes, including improving the stamina, for instance, of athletes. The installation for conducting general air cryotherapy comprises a closed-type cryogenic chamber (1) with a door (2) with heat insulation (3) and a heat sensor (8), a refrigeration machine (7) with a condenser and a power and control unit (9), and a coolant supply line (6), wherein the refrigeration machine (7) has two cascades, and an evaporator (4) with a ventilator (5) is installed into the ceiling or wall of the cryogenic chamber (1) and is connected by means of the coolant supply line (6) to the double-cascade refrigeration machine (7), and wherein a heat control valve (12) is installed at the inlet to the evaporator (4), and the cryogenic chamber (1) is equipped with a valve for equalizing pressure with the outside environment (11), and wherein said valve (11) has an electric heater, the door (2) of the cryogenic chamber (1) is made entirely transparent and is equipped, as is the frame thereof, with an electric heater, and a control console with a sensor panel (13) is installed on the external surface of the cryogenic chamber (1).

09/17/15
20150259397 

Long acting trial receptor agonists for treatment of autoimmune diseases


Methods of treating an autoimmune disease such as rheumatoid arthritis, methods of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, methods of increasing the quantity of the anti-inflammatory regulatory t cells, and methods of slowing the progression of inflammation in a subject include systemically administering to the subject a pharmaceutical composition including an effective amount of a trail-conjugate. Preferably, the trail-conjugate is effective for at least 3 days, more preferably at least 7 days, without being part of a nanocomplex that modulates the circulation half-life or release kinetics of the trail-conjugate.
Theraly Pharmaceuticals Inc.


09/17/15
20150259363 

Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity


The present invention provides novel pyrimidine and pyridine compounds according to formula (i), formula (ii), formula (iii), formula (iv) and formula (v) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of bruton's tyrosine kinase..
Merck Patent Gmbh


09/17/15
20150259350 

Novel triazolopyrazine derivative and use thereof


The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-met tyrosine kinase activity..
Handok Inc.


09/17/15
20150258094 

Nanocarriers and their processing for diagnostics and therapeutics


The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis..
Rhode Island Hospital


09/17/15
20150258025 

Liposomal lupeol acetate and the use thereof in preparing drugs for rheumatoid arthritis


The present invention relates to a liposomal lupeol acetate (lipo-la) and its use in the treatment or prevention of rheumatoid arthritis (ra). The liposomal lupeol acetate of the present invention especially inhibits inflammatory responses and osteoclast generation (osteoclastogenesis) in the progression of rheumatoid arthritis (ra) at a half dose of the un-capsulated lupeol acetate, which may significantly reduce the incidence of ra and improve the therapeutic efficacy of lupeol acetate..
National Yang-ming University




Rheumatoid Arthritis topics: Rheumatoid Arthritis, Osteoarthritis, Autoimmune, Multiple Sclerosis, Immune Disease, Autoimmune Disease, Antibodies, Astaxanthin, Hyaluronate, Hyaluronic Acid, Joint Pain, Hyaluronan, Immune Diseases, Autoimmune Diseases, Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.


3.4687

4168

3 - 0 - 102